Walleye Capital LLC Puma Biotechnology, Inc. Transaction History

Walleye Capital LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$2.21 - $4.82 $64,874 - $141,491	-29,355 Reduced 59.67%	19,837 $61,000
Q4 2022 Feb 14, 2023	BUY	$2.12 - $5.08 $65,527 - $157,017	30,909 Added 169.06%	49,192 $208,000
Q3 2022 Nov 14, 2022	SELL	$2.27 - $3.84 $195,083 - $330,009	-85,940 Reduced 82.46%	18,283 $43,000
Q2 2022 Aug 08, 2022	SELL	$1.64 - $3.3 $188,098 - $378,490	-114,694 Reduced 52.39%	104,223 $297,000
Q1 2022 May 16, 2022	SELL	$2.13 - $3.24 $392,350 - $596,814	-184,202 Reduced 45.69%	218,917 $630,000
Q4 2021 Mar 03, 2022	BUY	$2.85 - $6.58 $1.15 Million - $2.65 Million	403,119 New	403,119 $1.23 Million
Q1 2020 May 15, 2020	SELL	$6.28 - $14.57 $174,584 - $405,046	-27,800 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$6.5 - $10.73 $180,700 - $298,294	27,800 New	27,800 $244,000
Q3 2019 Nov 14, 2019	SELL	$8.75 - $12.85 $24,500 - $35,980	-2,800 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$12.3 - $35.76 $34,440 - $100,128	2,800 New	2,800 $36,000
Q1 2019 May 15, 2019	SELL	$20.77 - $42.37 $56,203 - $114,653	-2,706 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$41.2 - $59.85 $111,487 - $161,954	2,706 New	2,706 $124,000

100

28.9M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $136M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.